911 related articles for article (PubMed ID: 9352388)
21. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
[TBL] [Abstract][Full Text] [Related]
22. Oral cocaine pharmacokinetics and pharmacodynamics in a cumulative-dose regimen: pharmacokinetic-pharmacodynamic modeling of concurrent operant and spontaneous behavior within an operant context.
Lau CE; Sun L; Wang Q; Simpao A; Falk JL
J Pharmacol Exp Ther; 2000 Nov; 295(2):634-43. PubMed ID: 11046099
[TBL] [Abstract][Full Text] [Related]
23. A pharmacokinetic and pharmacodynamic study of desmopressin: evaluating sex differences and the effect of pre-treatment with piroxicam, and further validation of an indirect response model.
Odeberg JM; Callréus T; Lundin S; Roth EB; Höglund P
J Pharm Pharmacol; 2004 Nov; 56(11):1389-98. PubMed ID: 15525445
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
Gumbleton M; Oie S; Verotta D
Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
[TBL] [Abstract][Full Text] [Related]
25. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
Strougo A; Zuurman L; Roy C; Pinquier JL; van Gerven JM; Cohen AF; Schoemaker RC
J Psychopharmacol; 2008 Sep; 22(7):717-26. PubMed ID: 18583433
[TBL] [Abstract][Full Text] [Related]
26. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
Keller F; Czock D; Zellner D; Giehl M
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
[TBL] [Abstract][Full Text] [Related]
27. Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats.
Castel-Branco MM; Falcão AC; Figueiredo IV; Caramona MM
Fundam Clin Pharmacol; 2005 Dec; 19(6):669-75. PubMed ID: 16313279
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic relationships for analgesics.
Suri A; Estes KS; Geisslinger G; Derendorf H
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of cloprednol.
Möllmann H; Hochhaus G; Rohatagi S; Barth J; Derendorf H; Krieg M; Weisser H; Möllmann AC
Int J Clin Pharmacol Ther; 1996 Jan; 34(1):1-5. PubMed ID: 8688990
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.
Ing Lorenzini K; Daali Y; Dayer P; Desmeules J
Basic Clin Pharmacol Toxicol; 2012 Mar; 110(3):219-26. PubMed ID: 21995512
[TBL] [Abstract][Full Text] [Related]
31. [Clinical pharmacology in development of new anticancer agents].
Sasaki Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
[TBL] [Abstract][Full Text] [Related]
32. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip.
Sung JH; Kam C; Shuler ML
Lab Chip; 2010 Feb; 10(4):446-55. PubMed ID: 20126684
[TBL] [Abstract][Full Text] [Related]
33. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
Höcht C; Opezzo JA; Bramuglia GF; Taira CA
Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-pharmacodynamic modelling: history and perspectives.
Csajka C; Verotta D
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):227-79. PubMed ID: 16404503
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic relationship.
Baggot JD
Ann Rech Vet; 1990; 21 Suppl 1():29S-40S. PubMed ID: 2080844
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature.
Martini C; Olofsen E; Yassen A; Aarts L; Dahan A
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):719-28. PubMed ID: 22111858
[TBL] [Abstract][Full Text] [Related]
37. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions.
Schwartz JB; Verotta D; Sheiner LB
J Pharmacol Exp Ther; 1989 Dec; 251(3):1032-8. PubMed ID: 2600802
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of TNF antagonists: how do they differ?
Nestorov I
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):12-8. PubMed ID: 15852249
[TBL] [Abstract][Full Text] [Related]
40. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.
Zhang Y; Huo M; Zhou J; Xie S
Comput Methods Programs Biomed; 2010 Sep; 99(3):306-14. PubMed ID: 20176408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
